OMERS ADMINISTRATION Corp Invests $5.06 Million in Biogen Inc. $BIIB

OMERS ADMINISTRATION Corp purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 23,421 shares of the biotechnology company’s stock, valued at approximately $5,060,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC lifted its holdings in Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after buying an additional 56 shares in the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after acquiring an additional 57 shares in the last quarter. Kera Capital Partners Inc. increased its position in shares of Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 58 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after acquiring an additional 65 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Biogen by 24.4% in the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB stock opened at $218.12 on Tuesday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a market cap of $32.23 billion, a P/E ratio of 38.61, a P/E/G ratio of 6.75 and a beta of 0.17. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $222.15. The stock’s 50 day simple moving average is $205.92 and its 200 day simple moving average is $194.87.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the business posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts predict that Biogen Inc. will post 12.39 EPS for the current year.

Analyst Ratings Changes

BIIB has been the subject of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and set a $300.00 price objective on shares of Biogen in a research note on Wednesday, July 29th. HSBC reissued a “reduce” rating and set a $157.00 price target on shares of Biogen in a research report on Monday, July 6th. Zacks Research raised shares of Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a report on Monday, July 13th. Finally, Barclays upped their target price on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $227.07.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.